Header Logo

Connection

JOHN FARMER to Humans

Back to Details
This is a "connection" page, showing publications JOHN FARMER has written about Humans.
JOHN FARMER
Connection Strength
0.248
Humans
  1. Strategies for multivessel revascularization in patients with diabetes: the FREEDOM trial. Curr Atheroscler Rep. 2014 Jul; 16(7):426.
    View in: PubMed
    Score: 0.010
  2. The effect of statins on skeletal muscle function: the STOMP trial. Curr Atheroscler Rep. 2013 Aug; 15(8):347.
    View in: PubMed
    Score: 0.009
  3. Aggressive statin therapy and the risk of malignancy. Curr Atheroscler Rep. 2013 Apr; 15(4):316.
    View in: PubMed
    Score: 0.009
  4. High-density lipoprotein and atherosclerosis: the role of antioxidant activity. Curr Atheroscler Rep. 2012 Apr; 14(2):101-7.
    View in: PubMed
    Score: 0.008
  5. Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis. Curr Atheroscler Rep. 2011 Apr; 13(2):107-14.
    View in: PubMed
    Score: 0.008
  6. Dysfunctional high-density lipoprotein and atherosclerosis. Curr Atheroscler Rep. 2010 Sep; 12(5):343-8.
    View in: PubMed
    Score: 0.007
  7. Statins as adjunctive therapy in the management of hypertension. Curr Atheroscler Rep. 2010 Sep; 12(5):349-54.
    View in: PubMed
    Score: 0.007
  8. Simvastatin with or without ezetimibe in familial hypercholesterolemia (the ENHANCE trial). Curr Atheroscler Rep. 2009 Mar; 11(2):81-2.
    View in: PubMed
    Score: 0.007
  9. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis (the SEAS trial). Curr Atheroscler Rep. 2009 Mar; 11(2):82-3.
    View in: PubMed
    Score: 0.007
  10. Nicotinic acid: a new look at an old drug. Curr Atheroscler Rep. 2009 Mar; 11(2):87-92.
    View in: PubMed
    Score: 0.007
  11. The role of statin therapy in the management of cardiomyopathies. Curr Atheroscler Rep. 2009 Mar; 11(2):118-23.
    View in: PubMed
    Score: 0.007
  12. Adjunctive interventions in myocardial infarction: the role of statin therapy. Curr Atheroscler Rep. 2008 Apr; 10(2):142-8.
    View in: PubMed
    Score: 0.006
  13. Role of insulin signaling in maintaining energy homeostasis. Endocr Pract. 2008 Apr; 14(3):373-80.
    View in: PubMed
    Score: 0.006
  14. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Diab Rep. 2008 Feb; 8(1):71-7.
    View in: PubMed
    Score: 0.006
  15. Obesity and inflammation: a new look at an old problem. Curr Atheroscler Rep. 2007 Aug; 9(2):134-8.
    View in: PubMed
    Score: 0.006
  16. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Atheroscler Rep. 2007 Aug; 9(2):162-8.
    View in: PubMed
    Score: 0.006
  17. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. Nat Clin Pract Cardiovasc Med. 2006 Dec; 3(12):664-72.
    View in: PubMed
    Score: 0.006
  18. Optimal low-density lipoprotein levels: evidence from epidemiology and clinical trials. Curr Atheroscler Rep. 2006 Mar; 8(2):157-62.
    View in: PubMed
    Score: 0.005
  19. The sympathetic nervous system and pathophysiology of congestive heart failure. Postgrad Med. 2005 Dec; 118(6 Suppl Beta-Blockers):6-11.
    View in: PubMed
    Score: 0.005
  20. Intensive versus moderate lipid lowering with statins in acute coronary syndromes. Curr Atheroscler Rep. 2005 Mar; 7(2):85-6.
    View in: PubMed
    Score: 0.005
  21. Reversal of atherosclerosis with aggressive lipid lowering. Curr Atheroscler Rep. 2005 Mar; 7(2):86-7.
    View in: PubMed
    Score: 0.005
  22. Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary. Curr Atheroscler Rep. 2005 Mar; 7(2):88-94.
    View in: PubMed
    Score: 0.005
  23. Hypertension and the metabolic syndrome. Curr Cardiol Rep. 2004 Nov; 6(6):427-33.
    View in: PubMed
    Score: 0.005
  24. Rationale for aggressive lipid lowering: evidence from clinical trials. Expert Rev Cardiovasc Ther. 2004 May; 2(3):305-9.
    View in: PubMed
    Score: 0.005
  25. Hypolipidemic therapy and cholesterol absorption. Curr Atheroscler Rep. 2004 Mar; 6(2):89-93.
    View in: PubMed
    Score: 0.005
  26. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. Am J Cardiol. 2003 Jul 03; 92(1A):3i-9i.
    View in: PubMed
    Score: 0.005
  27. Benefits of simvastin in cholesterol lowering. Curr Atheroscler Rep. 2003 Mar; 5(2):93-4.
    View in: PubMed
    Score: 0.004
  28. Benefits of atorvastatin in cholesterol lowering. Curr Atheroscler Rep. 2003 Mar; 5(2):94-5.
    View in: PubMed
    Score: 0.004
  29. Statins and myotoxicity. Curr Atheroscler Rep. 2003 Mar; 5(2):96-100.
    View in: PubMed
    Score: 0.004
  30. Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited. Catheter Cardiovasc Interv. 2002 Aug; 56(4):474-7.
    View in: PubMed
    Score: 0.004
  31. Dyslipidemia and the vulnerable plaque. Prog Cardiovasc Dis. 2002 May-Jun; 44(6):415-28.
    View in: PubMed
    Score: 0.004
  32. Learning from the cerivastatin experience. Lancet. 2001 Oct 27; 358(9291):1383-5.
    View in: PubMed
    Score: 0.004
  33. The renin angiotensin system as a risk factor for coronary artery disease. Curr Atheroscler Rep. 2001 Mar; 3(2):117-24.
    View in: PubMed
    Score: 0.004
  34. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000 Sep; 23(3):197-213.
    View in: PubMed
    Score: 0.004
  35. Renin angiotensin system and ASCVD. Curr Opin Cardiol. 2000 May; 15(3):141-50.
    View in: PubMed
    Score: 0.004
  36. Coronary heart disease: clinical trials review. Curr Atheroscler Rep. 2000 May; 2(3):189-93.
    View in: PubMed
    Score: 0.004
  37. Pleiotropic effects of statins. Curr Atheroscler Rep. 2000 May; 2(3):208-17.
    View in: PubMed
    Score: 0.004
  38. Role of tumour necrosis factor-alpha in the progression of heart failure: therapeutic implications. Drugs. 2000 Apr; 59(4):745-51.
    View in: PubMed
    Score: 0.004
  39. Economic implications of lipid-lowering trials: current considerations in selecting a statin. Am J Cardiol. 1998 Sep 24; 82(6A):26M-31M.
    View in: PubMed
    Score: 0.003
  40. Aggressive lipid therapy in the statin era. Prog Cardiovasc Dis. 1998 Sep-Oct; 41(2):71-94.
    View in: PubMed
    Score: 0.003
  41. Endocarditis. Curr Opin Cardiol. 1997 Mar; 12(2):123-30.
    View in: PubMed
    Score: 0.003
  42. Choosing the right lipid-regulating agent. A guide to selection. Drugs. 1996 Nov; 52(5):649-61.
    View in: PubMed
    Score: 0.003
  43. Current and future therapeutic approaches to hyperlipidemia. Adv Pharmacol. 1996; 35:79-114.
    View in: PubMed
    Score: 0.003
  44. Antihyperlipidaemic agents. Drug interactions of clinical significance. Drug Saf. 1994 Nov; 11(5):301-9.
    View in: PubMed
    Score: 0.002
  45. Association between preoperative diuretic use and in-hospital outcomes after cardiac surgery. Cardiovasc Ther. 2013 Oct; 31(5):291-7.
    View in: PubMed
    Score: 0.002
  46. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. Clin Ther. 1992 Sep-Oct; 14(5):708-17.
    View in: PubMed
    Score: 0.002
  47. Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients. J Heart Lung Transplant. 2005 Jan; 24(1):46-51.
    View in: PubMed
    Score: 0.001
  48. Managing heart failure with immunomodulatory agents. Cardiol Clin. 2001 Nov; 19(4):617-25.
    View in: PubMed
    Score: 0.001
  49. The implications for cardiac recovery of left ventricular assist device support on myocardial collagen content. Am J Surg. 2000 Dec; 180(6):498-501; discussion 501-2.
    View in: PubMed
    Score: 0.001
  50. Tirofiban for cocaine-induced coronary artery thrombosis: a novel therapeutic approach. Circulation. 1999 Nov 02; 100(18):1939.
    View in: PubMed
    Score: 0.001
  51. Tumor necrosis factor-alpha: a mediator of disease progression in the failing human heart. Chest. 1999 Apr; 115(4):1170-4.
    View in: PubMed
    Score: 0.001
  52. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation. 1999 Feb 16; 99(6):736-43.
    View in: PubMed
    Score: 0.001
  53. Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. Circulation. 1998 Nov 10; 98(19):2017-23.
    View in: PubMed
    Score: 0.001
  54. Progressive deterioration of coronary flow reserve after heart transplantation. Am Heart J. 1998 Sep; 136(3):504-9.
    View in: PubMed
    Score: 0.001
  55. Images in cardiovascular medicine. Fistula between left main, left anterior descending, and pulmonary arteries. Circulation. 1998 May 26; 97(20):2091-2.
    View in: PubMed
    Score: 0.001
  56. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol. 1997 Dec; 8(6):354-61.
    View in: PubMed
    Score: 0.001
  57. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997 Aug 01; 80(3):278-86.
    View in: PubMed
    Score: 0.001
  58. Association of angiotensin I-converting enzyme gene polymorphism with myocardial ischemia and patency of infarct-related artery in patients with acute myocardial infarction. J Am Coll Cardiol. 1997 Jun; 29(7):1468-73.
    View in: PubMed
    Score: 0.001
  59. Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects. J Lipid Res. 1996 Jun; 37(6):1298-308.
    View in: PubMed
    Score: 0.001
  60. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. Am J Cardiol. 1994 May 26; 73(14):42D-49D.
    View in: PubMed
    Score: 0.001
  61. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol. 1991 Feb; 14(2):146-51.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.